NLRP3 and myocardial infarction: Colchicine, which inhibits tubulin polymerization and the assembly of the multimeric NLRP3 inflammasome, reduces major cardiovascular events (MACE) in patients with chronic stable coronary artery disease[53,54] as well as those with recent myocardial infarction[55].